ArticleThrombosis journal2025
Combination of antithrombin and soluble thrombomodulin for early prediction of sepsis-Induced disseminated intravascular coagulation.
Article in Thrombosis journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association between antithrombin levels and prognosis in patients with sepsis: a retrospective cohort study based on the MIMIC-IV and MIMIC-III databases.Journal of intensive care · 2026Article
- Angiopoietin-2 Surpasses Soluble Thrombomodulin and Syndecan-1 in Characterizing Septic Shock and Predicting Mortality--A Prospective Observational Study.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTo identify early diagnostic biomarkers for sepsis-induced disseminated intravascular coagulation, we investigated the relationship between the novel coagulation biomarkers and antithrombin with the development of Disseminated intravascular coagulation post-admission, as well as the prognosis of patients with sepsis.
methodsWe retrospectively collected data from septic patients admitted to the Emergency Intensive Care Unit (EICU) of a teaching hospital between October 2021 and September 2023. Multivariate logistic regression analysis was performed to identify risk factors, and receiver operating characteristic (ROC) curve analysis was used to assess the performance of the predictive model. In addition, non-parametric bootstrap analysis with 1,000 replications was conducted to evaluate the internal stability and empirical power of the predictive models, particularly given the limited sample size.
resultsAmong 91 septic patients, 15 were diagnosed with DIC. Soluble thrombomodulin (OR: 1.28, 95% CI: 1.033-1.586, P = 0.024) and antithrombin activity (OR: 0.887, 95% CI: 0.792-0.994, P = 0.039) were identified as independent risk factors for the development of DIC in septic patients. The area under the curve (AUC) for soluble thrombomodulin and antithrombin was 0.788 and 0.757, respectively. When combined, the AUC increased to 0.858. Prothrombin Time (HR: 1.058, 95% CI: 1.016-1.102, P = 0.007) and APACHE II score (HR: 1.071, 95% CI: 1.005-1.141, P = 0.035) were identified as independent risk factors for 28-day mortality in septic patients. When combined, the AUC increased to 0.834. Bootstrap validation demonstrated strong discriminatory performance of both models, with a mean bootstrap AUC of 0.865 (empirical power = 0.994) for the DIC prediction model, and 0.836 (empirical power = 0.996) for the 28-day mortality model, further supporting the robustness and reliability of the findings despite the small sample size.
conclusionElevated soluble thrombomodulin and decreased antithrombin may be associated with the early onset of disseminated intravascular coagulation in sepsis, but showed limited predictive value for 28-day mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.